Skip to content
Review Open access

MICROBIOME MODULATION THERAPY IN ORAL DISEASES: A NARRATIVE REVIEW

Sep 2026 · Genetics and Molecular Research · 0 citations · 17 references

Abstract

Background: The major oral diseases are no longer understood as infections by single pathogens but as ecological disorders, in which a resident microbial community shifts from a symbiotic to a dysbiotic state under environmental pressure. This reframing implies that therapy might restore the community rather than eliminate it, and has produced a large literature on probiotics, prebiotics, postbiotics, targeted antimicrobials and microbiota transplantation. Objective: To evaluate microbiome modulation therapy across the spectrum of oral disease according to the level of evidence each strategy has attained, and to identify why a field with abundant randomised trials has produced so little that has changed practice. Methods: A narrative review was conducted. PubMed, Embase, the Cochrane Library and ClinicalTrials.gov were searched on microbiota-modulating interventions in dental caries, periodontitis, peri-implant disease, oral candidiasis, halitosis and cancer therapy-induced oral mucositis. Randomised trials, meta-analyses, observational studies, preclinical work and trial registrations were eligible. Findings: Evidence is extensive but varies in quality and strength. Probiotics reduce caries in children, but not adults; improve periodontitis short-term when added to mechanical debridement; reduce bleeding, but not probing depth, in peri-implant mucositis; and lessen severe mucositis during cancer therapy. An 8% arginine dentifrice reduced caries increment versus fluoride in a 6,000-child phase 3 trial, making substrate modification the strongest-supported ecological strategy. Postbiotics, synbiotics, and nitrate approaches remain largely limited to surrogate microbiological outcomes, while C16G2 completed phase 2 without published efficacy data. Replacement therapy, phage therapy, and oral microbiota transplantation remain preclinical or early-stage. Conclusions: The obstacle in this field is not a shortage of trials but a shortage of trials that measure disease. Reliance on microbiological surrogates, the transience of exogenous colonisation, and the regulation of most products as foods rather than medicines have together produced a literature that is large, positive and largely unable to support clinical recommendation.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.